Paan is not classified as a controlled drug in most countries, but it contains a genuinely psychoactive substance that acts on the brain, causes dependence, and produces withdrawal symptoms when you stop using it. The active ingredient is arecoline, a naturally occurring alkaloid found in the areca nut (betel nut) that sits at the center of most paan preparations. Arecoline is a stimulant that affects the same receptor systems as nicotine, and the World Health Organization’s cancer research agency classifies areca nut as a Group 1 carcinogen, the highest risk category.
What Paan Actually Contains
Paan is a preparation, not a single substance. At its simplest, it’s a betel leaf wrapped around a filling that typically includes areca nut, slaked lime (calcium hydroxide), and various spices or sweeteners. The specific contents vary widely. “Meetha paan” (sweet paan) skips the tobacco and adds rose petal jam, coconut, fennel seeds, or other flavoring. Tobacco paan includes chewing tobacco alongside the areca nut. Gutkha is a commercially packaged version containing areca nut, slaked lime, tobacco, spices, and catechu sold in small pouches.
Regardless of whether tobacco is included, the areca nut itself is the primary psychoactive component. Four alkaloids are present in areca nut: arecoline, arecaidine, guvacoline, and guvacine. Arecoline is the dominant one and the main reason people feel a buzz from chewing paan. The slaked lime isn’t just filler. It creates an alkaline environment in the mouth that helps release arecoline from the nut more efficiently, intensifying its effects.
How Arecoline Acts on the Brain
Arecoline is a psychoactive alkaloid that mimics acetylcholine, a key chemical messenger in the nervous system. It activates two types of receptors: muscarinic receptors (which regulate gland secretion, blood vessel tone, and smooth muscle) and nicotinic receptors (which influence alertness, muscle activity, and mood). This dual action makes it a stimulant for both the central nervous system and the autonomic nervous system, the part that controls involuntary functions like heart rate and digestion.
The subjective effects include increased feelings of well-being, heightened alertness, and a sense of greater endurance. Animal studies show that arecoline significantly alters levels of serotonin in the brain, reducing them. This decrease in serotonin may be one mechanism behind the stimulant effect. The experience is often compared to a mild nicotine buzz, which makes sense given that arecoline and nicotine share a common receptor target.
Dependence and Withdrawal
Regular paan use can lead to genuine substance dependence. The pattern follows the same trajectory as other addictive substances: social or cultural initiation leads to habitual use, which leads to tolerance (needing more to feel the same effect), craving, and eventually loss of control over consumption. Researchers have applied DSM-5 diagnostic criteria, the same framework used for alcohol and nicotine addiction, to evaluate betel nut dependence.
Stopping abruptly after chronic use disrupts the brain’s cholinergic system, the network of signaling pathways that arecoline has been artificially stimulating. This produces classic withdrawal symptoms: anxiety, restlessness, irritability, and difficulty concentrating. Habitual users also report increased depressive symptoms and reduced sociability. In clinical settings, medications that modulate glutamate receptors have shown some success in reducing cravings and easing withdrawal, and antidepressant treatment has been shown to reduce the severity of betel nut use by roughly fourfold.
Betel nut use typically begins in late adolescence, between ages 15 and 18, and peaks in the 20 to 40 age group. An estimated 600 million people worldwide use areca nut products.
Cancer and Other Health Risks
The International Agency for Research on Cancer (IARC) classifies areca nut as a Group 1 carcinogen. This is the same category as tobacco and asbestos, meaning there is sufficient evidence that it causes cancer in humans. Importantly, this classification applies to areca nut on its own, not just when combined with tobacco. Betel quid without tobacco causes oral cancer. Betel quid with tobacco causes oral cancer plus cancers of the pharynx and esophagus. There is also suggestive evidence linking betel quid chewing to liver cancer, bile duct cancer, and cancers of the stomach and cervix.
One of the most common consequences of long-term paan chewing is oral submucous fibrosis, a condition where the tissue inside the mouth gradually becomes stiff and leathery. In a study of 1,000 habitual chewers, 6.3% had developed the condition. It starts with a burning sensation and a pale, marble-like appearance of the inner cheeks. Over time, tough fibrous bands form in the tissue, progressively restricting how far you can open your mouth. In severe cases, mouth opening is reduced by more than two-thirds, the tongue may become partially immobilized, and ulcers develop on the oral lining. Oral submucous fibrosis is itself considered a precancerous condition.
Legal Status
Paan and areca nut occupy a legal gray zone in most Western countries. They are not scheduled as controlled substances the way cocaine or cannabis are in many jurisdictions, but they face increasing regulatory action. The U.S. Food and Drug Administration does not recognize areca nut as safe for human consumption. Under an active import alert, the FDA detains shipments of food products that contain areca nuts, including powders, extracts, finished dietary supplements, and bulk ingredients, without even requiring a physical examination first. The agency cites arecoline’s cytotoxic, genotoxic, mutagenic, and carcinogenic effects as the basis for this action.
In several Indian states, gutkha and flavored chewing tobacco have been banned under food safety regulations, though enforcement is uneven. Countries like Australia and parts of the Pacific Islands have introduced public health campaigns targeting betel nut use. In South and Southeast Asia, where paan chewing is deeply embedded in culture, it remains legal and widely available, sold at street-side stalls with little regulatory oversight.
How the Body Processes It
When you chew paan, arecoline is absorbed through the lining of the mouth and enters the bloodstream. The body breaks it down into at least 11 different metabolites. The major breakdown product is a compound called N-methylnipecotic acid, which accounts for roughly 14% to 30% of the dose that shows up in urine within 12 hours. Very little arecoline itself makes it through unchanged, only about 0.3% to 0.4% of the original dose. This means the body processes it quickly, which partly explains why habitual users chew frequently throughout the day to maintain the effect.
The rapid metabolism also means that by the time symptoms of dependence develop, the brain has already adapted to a cycle of repeated stimulation and clearance. This cycle of quick absorption, brief effect, and rapid clearance is a pattern shared with other habit-forming stimulants.
So Is It a Drug?
By any pharmacological definition, yes. Arecoline is a psychoactive substance that crosses into the brain, activates specific receptors, alters neurotransmitter levels, produces mood changes, creates tolerance, and causes withdrawal. The fact that it comes wrapped in a leaf with sweet spices rather than in a pill or a cigarette doesn’t change what it does to the body. It shares a receptor target with nicotine, carries a higher cancer classification than many regulated substances, and the FDA considers it unsafe for consumption. What paan lacks is a formal legal classification as a controlled substance in most countries, which is more a reflection of cultural history and regulatory gaps than of its actual risk profile.